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Abstract: Background. This paper aimed to prospectively evaluate the safety of embolization therapy
of pulmonary arteriovenous malformations (PAVMs) for the detection of cerebral infarctions by pre-
and post-interventional MRI. Method One hundred and five patients (male/female = 44/61; mean
age 48.6+/−15.8; range 5–86) with pre-diagnosed PAVMs on contrast-enhanced MRA underwent
embolization therapy. The number of PAVMs treated in each patient ranged from 1–8 PAVMs.
Depending on the size and localization of the feeding arteries, either Nester-Coils or Amplatzer
vascular plugs were used for embolization therapy. cMRI was performed immediately before, and
at the 4 h and 3-month post-embolization therapy. Detection of peri-interventional cerebral emboli
was performed via T2w and DWI sequences using three different b-values, with calculation of ADC
maps. Results Embolization did not show any post-/peri-interventional, newly developed ischemic
lesions in the brain. Only one patient who underwent re-embolization and was previously treated
with tungsten coils that corroded over time showed newly developed, small, diffuse emboli in
the post-interventional DWI sequence. This patient already had several episodes of brain emboli
before re-treatment due to the corroded coils, and during treatment, when passing the corroded coils,
experienced additional small, clinically inconspicuous brain emboli. However, this complication was
anticipated but accepted, since the vessel had to be occluded distally. Conclusion Catheter-based
embolization of PAVMs is a safe method for treatment and does not result in clinically inconspicuous
cerebral ischemia, which was not demonstrated previously.
Keywords: hereditary hemorrhagic telangiectasia/HHT/osler’s disease; cerebral ischemic lesions;
catheter based embolization therapy; pulmonary arteriovenous malformations
1. Introduction
Arteriovenous malformations (AVMs) in patients with Hereditary Hemorrhagic
Telangiectasia (HHT; Osler’s disease) are malformations in which arteries and veins are
directly connected, due to the absence of intervening capillaries [1]. The most common
clinical symptoms are spontaneous and recurrent epistaxis, as well as Telangiectasias (small
AVMs) on the lips, tongue, buccal mucosa, face, chest, and fingers [2]. Larger AVMs
become symptomatic in the lungs, liver, gastrointestinal tract, or brain; thus, complications
from severe bleeding or shunting with possible consecutive cerebrovascular incidents may
occur. Pulmonary arteriovenous malformations (PAVMs) are defined as pathologic com-
munications between pulmonary arteries and pulmonary veins, resulting in a right-to-left
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shunt [3,4]. Larger shunts may result in hypoxemia manifesting with dyspnea, poten-
tially increasing the risk of paradoxical cerebral embolization [5], and, in consequence,
the risk of increased morbidity and mortality. Of the approaches to treating patients with
PAVMs, catheter embolization, either with coils or vascular plugs [6], is considered the
treatment of choice because of its high success rate and reduced invasiveness compared to
lung surgery [7,8], and because embolization more favorably respects the unaffected lung
parenchyma compared to surgical resection [9].
Reperfusion or recanalization of initially successfully treated PAVMs is the most
common cause of recurrence after coil embolization [10–12]. However, interventionalists
can minimize the risk of reperfusion by using dense “packing” techniques that result in
the complete cross-sectional occlusion of feeding arteries [13]. Thus, PAVM embolization
with Amplatzer vascular plugs (AVP) has been shown to achieve relatively high mid-term
success rates in terms of recurrence or recanalization, even in bilateral treatment [14–17].
In general, a low reperfusion rate is noted in the long-term due to late re-opening [6,18].
The incidence of stroke in patients with HHT ranges between 9 and 18% [19,20].
Although the occurrence of clinically conspicuous stroke seems to be lower in patients
with PAVMs treated with embolization therapy than in patients with untreated, persistent
PAVMs [19–22], little is yet known about the rate of clinically inconspicuous ischemic brain
lesions associated with PAVMs. In contrast, procedure-associated, clinically inconspicu-
ous ischemic brain lesions are common in up to 40% of patients undergoing supra-aortal
endovascular procedures or neurovascular interventions, such as carotid stenting or en-
darterectomy [23,24].
To our knowledge, no data are yet available on the incidence of peri-interventional
cerebral ischemia occurring during catheter-based embolization of PAVMs. Therefore,
the aim of our investigational study was to prospectively evaluate the incidence of peri-
interventional cerebrovascular incidents in patients with HHT referred for catheter-based
embolization of PAVMs.
2. Materials and Methods
2.1. Patients
This single-center, prospective study observational was approved by the institutional
review board. Written informed consent for both catheter-based embolization and the use
of imaging data was obtained from all patients or legal guardians.
All patients included in the study suffered from HHT, confirmed either by genetic
testing or, in most cases, based on Curaçao criteria [1,25]. Independently of clinical presen-
tation and symptoms, each included patient had at least one PAVM with a feeding artery
diameter of at least 2 mm diagnosed by contrast-enhanced MR angiography (CE-MRA),
and in a few cases, CT imaging.
Patients were ineligible for inclusion if they had a severe allergy to iodine contrast
agents, significantly impaired renal function (GFR < 15 mL/min), and/or severely im-
paired blood coagulation (INR > 2) or platelet count (<50.000/dL). Likewise, patients
were ineligible for inclusion if they were contraindicated for MRI (e.g., for implanted
cardiac pacemakers).
2.2. Embolization Technique
Access through the right common femoral vein was obtained after local anesthesia of
the groin region. A 7F sheath was inserted and the common pulmonary artery was probed
with the help of a 5F pigtail catheter and a bentson guidewire. Diagnostic pulmonary
angiograms were performed to locate and visualize the PAVMs. Afterwards, using a Rosen
guidewire, a Cook White Lumax guiding catheter (Cook Medical) or a coaxial system
consisting of a Neuron 6F Long Sheath and a Neuron 6F Select Catheter (Penumbra) was
inserted, and selective catheterization of the segmental and subsegmental pulmonary
artery feeding the PAVM was performed, using the coaxial system. Guidewires which
might perforate the aneurysm sac were avoided. The number and diameters of the feeding
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arteries of the evaluated PAVMs were identified after contrast medium injection. The
PAVMs were classified as simple or complex based on the number of feeding arteries, as
described elsewhere [26,27].
Depending on the size of the main feeding artery and the anatomical situation, either
Nester-Coils (Cook, USA) or Amplatzer vascular plugs II/IV (St. Jude Medical) were used
for embolization. These were introduced through a guiding catheter of appropriate size
under a water seal. The diameter of the device was chosen to be approximately 30% larger
than the size of the main feeding artery. The plug or coil was then placed as distally as
possible in the feeding artery with sparing of the PAVM itself.
The choice of embolization device was made according to the length of the available
landing zone, which is the distance between the PAVM and the first proximal pulmonary
subsegmental artery. In the case of amplatzer vascular plugs, the position of the device was
checked by Digital Subtraction Angiography (DSA) immediately after device placement. If
the position of the device was deemed adequate and satisfactory, the device was released;
otherwise, the device was retrieved and repositioned as necessary.
Post-embolization angiography was performed after satisfactory device placement to
confirm the total occlusion of the PAVM.
Immediately before the procedure, each patient received IV injection of 2500 IE Heparin.
The number of PAVMs treated in each patient ranged from one to eight, either treated
in one intervention or across multiple interventions, depending on the duration and
complexity of the procedure as well as the patient’s general condition of compliance
during angiography.
2.3. Pre- and Post-Interventional Pulmonary MRI
Pulmonary CE-MRA to evaluate PAVMs before and after intervention was performed
on a 1.5 Tesla (T) magnet (Magnetom Aera, Siemens Medical Systems, Erlangen, Germany)
with a 16-channel phased-array coil. The imaging protocol consisted of dynamic, time-
resolved, contrast-enhanced MRA, and high-resolution, pulmonary arterial- and early
venous-phase, contrast-enhanced MRA sequences.
Time-resolved MRA was performed after injection of a small contrast bolus
(0.025 mmol/kg of gadobenate dimeglumine [MultiHance™, Bracco] or 0.05 mmol/kg
of gadoteridol [ProHance™, Bracco]). The sequence parameters were as follows: repe-
tition time/echo time (TR/TE) = 2.7/1.0 ms, average field of view = 40 × 29 cm, slice
thickness = 1.5 mm, 140–160 slices, BW = ±113 kHz. The temporal resolution of the
sequence was 3 sec/dataset with a total of 72 slices. k-space sampling was performed
via key-hole imaging (TWIST). The true spatial resolution was 1.2 × 1.2 × 1.5 mm3,
which was interpolated to 0.7 × 0.7 × 1.0 mm3 by zero-filling.
High-resolution, contrast-enhanced Angio 3D MRA was then performed using
the timings established in the time-resolved study. Initially, breath-hold, non-contrast
enhanced, T1-weighted, spoiled gradient recalled echo (FLASH 3D) images were ac-
quired. The sequence parameters were as follows: TR/TE = 2.81/1.07 ms, average
field of view = 40 × 29 cm, slice thickness = 1.3 mm, 140–160 slices, BW 540 kHz. The
temporal resolution of the sequence was 2.2 s/dataset with a total number of up to
160 slices. The true spatial resolution was 1.3 × 1.3 × 1.5 mm3, which was interpolated
to 1.1 × 1.1 × 1.3 mm3 by zero-filling. Thereafter, the identical FLASH 3D sequence was
repeated after injection of 0.075 mmol/kg of gadobenate dimeglumine or 0.15 mmol/kg
of gadoteridol at a flow rate of 2 mL/s at end-inspiration, followed by a flush of 30 mL
normal saline [28]. The scan time varied depending on patient size and the number of
slices required. Likewise, the acquisition time varied with the size of the patient and the
number of phase-encoded steps needed to maintain resolution. Iterative reconstruction
was applied to provide an effective acceleration factor of approximately 4.0, which also
varied slightly depending on the number of slices.
The first acquisition was the arterial phase of the pulmonary circulation, and possible
shunts between the bronchial arteries and pulmonary veins were also visualized during this
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phase. Subsequently, a second full acquisition was performed in which normal pulmonary
veins were visible. For all acquisitions, patients were instructed to hold their breath at
end-inspiration. The total acquisition time for the entire MRA protocol ranged between 5
and 6 min. All examinations were performed as part of the daily clinical routine. Follow-up
of all interventional procedures by means of CE-MRA was performed routinely, first at
3 months post-intervention and then at yearly intervals.
2.4. Cerebral MRI
Cerebral MRI was performed immediately before the embolization, as well as at
the 4 h and 3-month post-embolization therapy. For detection of peri-interventional
cerebral ischemic lesions, T2w imaging (T2-Turbo Spin Echo [TSE], slice thickness 3 mm,
TR = 5000 ms, TE = 92 ms, BW 191 kHz) and Diffusion Weighted Imaging (DWI; echo planar
imaging sequence, slice thickness 5 mm, TR = 6300 ms, TE= 89 ms, BW: 1132 kHz) using
three different b-values (b = 0, 400, 800) with calculation of ADC maps were performed.
Any new lesion occurring between the pre- and post-interventional cerebral MRI scans
on either sequence was considered a new cerebrovascular incident associated with the
intervention. Additional pre- and post-contrast T1-weighted TSE, FLAIR, and susceptibility
weighted sequences were acquired as part of the initial screening to rule out cerebral AVMs,
including micro-AVMs.
2.5. Statistical Analysis
The characteristics of all participants were transcribed into software (Excel, ver-
sion2011; Microsoft, Redmond, Wash) for subsequent analysis. Central tendency was
measured by the mean, while range and standard deviation were used to measure the
dispersion of data.
3. Results
Between 2008 and 2019, a total of 105 patients (male/female = 44/61; mean age
48.6 +/− 15.8 (range 5–86)) met the inclusion criteria and were included in the study.
Overall, 289 PAVMs were embolized across these 105 patients. This total included 47
(16.3%) re-perfused PAVMs in 35 (33.3%) patients. A total of 871 embolization coils and
119 vascular plugs were used. No technical difficulties occurred during placement or
deployment of the embolization device.
No cerebrovascular incidents directly ascribable to the embolization procedure oc-
curred. Small, diffuse, but clinically inconspicuous acute cerebral lesions were detected in
one patient (1/105; 0.95%) on DWI-MRI at 4 h after the interventional procedure, but this
patient had previously undergone embolization of a vessel with tungsten coils that had
corroded over time. Since re-embolization into the previously placed tungsten coils was
considered necessary and unavoidable, the possibility of new cerebral emboli resulting
from small particles of corroded tungsten coil released during the re-embolization was
anticipated prior to the treatment. The re-embolization of this patient was successful,
and no further brain lesion and no clinical symptoms of stroke were encountered over a
follow-up period of 8 years.
No other patient, whether undergoing primary embolization or re-embolization,
showed any signs or symptoms of cerebrovascular incidents, and no newly developed
clinically inconspicuous ischemic brain lesions were observed on MRI.
Clinical examples of diagnosis and treatment are depicted in Figures 1–4.




Figure 1. Cerebral DWI (b = 800) demonstrating subacute cerebral ischemia, in this case prior to 
embolization of multiple PAVMs. The newly developed lesion arose between screening for PAVM 
and the day of interventional therapy, but the patient did not exhibit any clinical signs or 
symptoms. This example highlights the importance of DWI for the detection of pre-existing 
cerebral ischemia, as well as peri-interventional cerebral insult. 
   
Figure 2. (a–c) CT of a patient, demonstrating a giant complex PAVM of the right lung (a). The PAVM is depicted after 
selective catheterization of the feeding artery on DSA after manual contrast medium injection (b). DSA of the PAVM 
directly after positioning of an amplatzer vascular plug II (arrow) with already reduced flow in the PAVM (c). 
Figure 1. Cerebral DWI (b = 800) demonstrating subacute cerebral ischemia, in this case prior to
embolization of multiple PAVMs. The newly developed lesion arose between screening for PAVM
and the day of interventional therapy, but the patient did not exhibit any clinical signs or symptoms.
This example highlights the importance of DWI for the detection of pre-existing cerebral ischemia, as
well as peri-interventional cerebral insult.
Fig. 2 a-c 
 
Example of a large PAVM of the right lung, treated with an amplatzer vascular plug. 
Fig. 2a shows a giant complex PAVM of the right lung. In Fig. 2b the PAVM is depicted after selec-
tive catheterization of the feeding artery on DSA after manual contrast medium injection. Fig. 2c 
shows the PAVM directly aft r positioning of an amplatzer vascular plug II (arrow) with already re-
duced flow in the AVM. 
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Figure 2. (a–c) CT of a patient, demonstrating a giant complex PAVM of the right lung (a). The PAVM is depicted after
selective catheterization of the feeding artery on DSA after manual contrast medium injection (b). DSA of the PAVM directly
after positioning of an amplatzer vascular plug II (arrow) with already reduced flow in the PAVM (c).
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Figure 3. (a–c) Re-perfused PAVM after previous treatment elsewhere. Contrast-enhanced MRA (a) shows two large,
re-perfused PAVMs (arrows) with early enhancement of the draining vein. In (b) the DSA of one re-perfused PAVM is
shown, depicting insufficient dense packing of coils resulting in reperfusion of the vessel. No guide wire should be used,
since small thrombi from the coils might be mobilized and lead to systemic emboli. In (c) the second re-perfused PAVM
is demonstrated, showing only small coils at the wall of the vessel. Embolization was performed proximal to the treated
vessel segment to avoid possible migration of the coils.
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perfused PAVMs (arrows) with early enhancement of the draining vein. In (b) the DSA of one re-perfused PAVM is shown, 
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Figure 4. Cont.
J. Clin. Med. 2021, 10, 887 7 of 11





Figure 4. (a–d) A giant re-perfused PAVM in the lower right lobe. In this case, pre-interventional DSA (a) shows two large 
feeding vessels originating from a common trunk, resulting in embolization being performed at the level of the bifurcation. 
With DSA performed just after implantation, (b) shows the amplatzer plug II still connected to the wire. Optimal 
positioning is depicted. The dynamic series in (c) shows the vascular plug (arrow) still penetrable to contrast medium, 
however, flow is already reduced. At 5 min post-implantation of the vascular plug (d), the feeding artery of the re-perfused 
PAVM is completely occluded. 
4. Discussion 
In general, all vascular interventions involving the thoracic or the supra-aortal 
regions bear the risk of clinically (in)conspicuous cerebral ischemic lesions, as reported 
for transcatheter aortic valve implantation or in carotid angioplasty [29,30]. Thus, all 
patients undergoing thoracic or supra-aortal interventions are prone to dementia and 
cognitive dysfunction [31,32]. Our prospective study on the occurrence of procedure-
associated brain lesions following catheter-based embolization of PAVMs in patients with 
HHT suggests that this procedure carries a very low risk of cerebrovascular incidents in 
this patient population. Although our study can only be considered preliminarily, only 
one individual exhibited newly formed, clinically inconspicuous, small and diffuse 
cerebral emboli at 4 h after the interventional procedure, and this patient was unique 
amongst the patients in our cohort due to the presence of corroded tungsten coils from 
previous interventions. Embolization of the vessel had to be performed proximally and 
distally to the corroded coils and thus, when forwarding the catheter through the 
corroded coils, the risk of additional small displaced fragments was unavoidable. 
Figure 4. (a–d) A giant re-perfused PAVM in the lower right lobe. In this case, pre-interventional DSA (a) shows two large
feeding vessels originating from a common trunk, resulting in embolization being performed at the level of the bifurcation.
With DSA performed just after implantation, (b) shows the amplatzer plug II still connected to the wire. Optimal positioning
is depicted. The dynamic series in (c) shows the vascular plug (arrow) still penetrable to contrast medium, however, flow
is already reduced. At 5 min post-impla tation of the vascular plug (d), the feeding artery of the re-perfused PAVM is
completely occlu ed.
4. Discussion
In general, all vascular interventions involving the thoracic or the supra-aortal re-
gions bear the risk of clinically (in)conspicuous cerebral ischemic lesions, as reported for
transcatheter ortic valve impla tation or in carotid angioplasty [29,30]. Thus, all patients
undergoing thoracic or supra-aortal interventions are prone to dementia and cognitive
dysfunction [31,32]. Our prospective study on the occurrence of procedure-associated brain
lesions following catheter-based embolization of PAVMs in patients with HHT suggests
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that this procedure carries a very low risk of cerebrovascular incidents in this patient
population. Although our study can only be considered preliminarily, only one individual
exhibited newly formed, clinically inconspicuous, small and diffuse cerebral emboli at 4 h
after the interventional procedure, and this patient was unique amongst the patients in our
cohort due to the presence of corroded tungsten coils from previous interventions. Em-
bolization of the vessel had to be performed proximally and distally to the corroded coils
and thus, when forwarding the catheter through the corroded coils, the risk of additional
small displaced fragments was unavoidable.
To our knowledge, this is the first study to report on the incidence of peri-procedural
cerebrovascular incidents following catheter-based embolization of PAVMs. Although the
incidence of ischemic stroke ranges between 9 and 18% in patients with HHT and patent
PAVMs [19,20,33–35], our findings suggest that embolization therapy does not significantly
impact the rate of further cerebrovascular incidents. Indeed, the one event noted in our
series can be ascribed to the embolization material used previously (tungsten coils) rather
than to the embolization procedure itself. Given the relatively high number of participants
and the high number of complex PAVMs warranting re-embolization therapy due to
reperfusion, our results confirm that embolization therapy is safe and highly effective for
the treatment of PAVMs in patients with HHT [36–38].
Available data regarding the occurrence of peri-interventional cerebrovascular inci-
dents measured with DWI sequences in cMRI suggest that new ischemic brain lesions
occur in up to 34% of patients treated for carotid stenting [23]. However, neurovascular in-
terventions are more prone to acute cerebral embolism. Moreover, studies investigating the
implementation of protection devices during carotid stenting have not shown statistically
significant reductions in the incidence of acute peri-interventional embolism [30,39,40].
There were some limitations to this study. First, as in all interventional studies, eval-
uation of peri-procedural complications requires expertise and experience. This was a
single-center study with procedures performed and assessed by only a few, very experi-
enced interventional radiologists. It is possible that a greater number of cerebrovascular
incidents might have occurred in this same patient cohort, had the interventions been
performed by less experienced physicians. However, it should be noted that PAVMs are a
complex pathology that warrant a certain degree of interventional experience by the treat-
ing physician, and that intervention would usually be undertaken at dedicated institutions
by experienced personnel. Second, we only evaluated safety in terms of cerebrovascular
incidents. Further studies are needed to evaluate the incidence of other potential complica-
tions, such as chest pain, hemoptysis, and hemothorax. Moreover, cMRI readings could not
be blinded, since examiners were instructed to carefully look for new, small ischemic lesions
in the brain, therefore being aware of the embolization therapy and patient’s disease.
In conclusion, to our knowledge, this is the first study to investigate the safety of
catheter embolization of PAVMs in patients with HHT in terms of cerebrovascular incidents.
Although further multi-center studies in larger patient populations are required to confirm
our preliminary results, our observational study reveals a very low rate of clinically
inconspicuous cerebral ischemia in patients with HHT undergoing interventional treatment
for PAVMs.
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HHT Hereditary Hemorrhagic Telangiectasia
(P)AVM (Pulmonary) Arteriovenous Malformation
AVP Amplatzer Vascular Plug
cMRI cerebral Magnetic Resonance Imaging
CE-MRA Contrast Enhanced Magnetic Resonance Angiography
DWI Diffusion Weighted Imaging
ADC Apparent Diffusion Coefficient
MR(I) Magnetic Resonance (Imaging)
GFR Glomerular Filtration Rate
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BW Body Weight
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